NSAIDs and colchicine are the mainstay of treatment for acute pericarditis, while IL-1 blockers offer a steroid-sparing option for recurrent cases.
Answers are grounded in this paper and cite their sources.
Supports current first-line therapy for acute pericarditis; leaves open optimal recurrence prevention strategies.
Acute pericarditis is a common cause of nonischemic chest pain. Tuberculosis is the leading cause of pericarditis in endemic areas and is treated with antitubercular therapy. In North America and Western Europe, pericarditis is typically idiopathic, develops after a viral infection, or develops following cardiac procedures or surgery. Treatment with NSAIDs and colchicine leads to a favorable prognosis in most patients, although 15% to 30% of patients develop recurrence. Patients with multiple recurrent pericarditis can have a disease duration of several years or more, are often treated with corticosteroids, and IL-1 blockers may be used for selected patients as steroid-sparing therapy.
No takes yet. Share an insight, caveat, or question.
Cremer et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: